News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neuronetrix, Inc. Study Bridges Gap Between Interesting Research And Practical Clinical Applications For Important Cognitive Biomarker


6/25/2014 6:43:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOUISVILLE, Ky., July 25, 2014 /PRNewswire/ -- Neuronetrix will be reporting at AAIC 2014 that neuro-electrophysiological measures recorded using the company's COGNISION System can be used to differentiate patients with mild Alzheimer's disease from healthy controls. Previous scientific studies have demonstrated the discriminatory power of these measures in highly controlled research environments. Neuronetrix's study demonstrated that these measures can be reliably recorded and analyzed in real world clinical settings.

The study included over 200 subjects from seven clinical sites across the US. All tests were administered by non-expert clinical staff and the data was automatically analyzed by the COGNISION System. The results include an exhaustive analysis of the complex electrophysiological features and show their statistical correlation to Alzheimer's disease.

In addition to their clinical utility, these biomarkers are particularly important in pharmaceutical development of pro-cognitive therapeutics by providing sensitive measures of drug effects.

"This study has confirmed COGNISION System's ability to bridge the gap between interesting scientific findings and practical clinical applications," said Marco Cecchi, PhD, Neuronetrix's Director of Research and Clinical Affairs. "Clinicians and pharmaceutical companies now have access to reliable biomarkers of Alzheimer's disease in real world clinical settings."

Study results will be presented at Alzheimer's Association International Conference (AAIC) in Copenhagen, Denmark from July 12-17, 2014, during a scientific oral session and at an ISTAART event.

About COGNISION

The COGNISION System is a proprietary neuro-electrophysiological device which provides objective assessments of cognitive function. COGNISION implements powerful and validated scientific methods in a practical, cost effective, and easy to use design.

About Neuronetrix

Neuronetrix, developer of the COGNISION System, is a leading neurotech company focused on providing physicians and scientists with accurate and meaningful information about brain processing. This information is critical in the understanding of complex brain function, diagnosis of cognitive disorders, and evaluating the effects of pro-cognitive therapies.

Information about Neuronetrix is available at http://www.neuronetrix.com or by contacting Daniel Lawson at dlawson@neuronetrix.com, or (502) 561-9040, x7003.

Contact:
Daniel Lawson
Neuronetrix
1044 E. Chestnut St.
Louisville KY 40204
(502) 561-9040, x7003
dlawson@neuronetrix.com
www.neuronetrix.com

SOURCE Neuronetrix



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES